成人费城染色体阳性急性淋巴细胞白血病可测量残留病意义:GRAAPH-2014研究
在GRAAPH-2014试验的264例成人Ph+ ALL患者中,每周期后同时定量BCR::ABL1与IG/TR标志。BCR::ABL1反应不能预测结局,而IG/TR阳性(≥0.01%)与较低DFS强相关;第2周期后IG/TR阳性及初诊WBC≥30×10⁹/L定义高危组,其4年DFS为56.5%对87.6%,异基因HSCT显著改善高危组DFS。
要点
- BCR::ABL1定量监测在成人Ph+ ALL中的预后意义受到挑战。
- 第2周期后IG/TR阳性(≥0.01%)与较低DFS强相关(HR 2.49)。
- 高危组(第2周期后IG/TR阳性且初诊WBC≥30×10⁹/L)4年DFS为56.5%对87.6%。
核心结论
- BCR::ABL1监测在成人Ph+ ALL中的意义受到挑战,IG/TR MRD具有预后作用。
- 本研究为利用MRD指导成人Ph+ ALL治疗策略提供了框架。
研究设计与样本
- GRAAPH-2014试验中264例患者,每周期后定量BCR::ABL1与IG/TR。
- 方案为4周期减低强度化疗联合尼洛替尼,随后行造血干细胞移植。
主要发现
- 228例中98例(43%)存在残留BCR::ABL1阳性非ALL细胞,定义为多系Ph+ ALL。
- 多系Ph+ ALL患者BCR::ABL1反应较差,但DFS相似(HR 0.83 [95%CI 0.49–1.41],P=.50)。
- BCR::ABL1反应未能预测结局;IG/TR阳性(≥0.01%)与较低DFS强相关:第2周期后HR 2.49(95%CI 1.40–4.40,P=.002),第4周期后HR 4.13(95%CI 1.82–9.38,P=.001)。
- 多因素分析中,第2周期后IG/TR阳性与初诊WBC≥30×10⁹/L均预测较差DFS,高危组4年DFS 56.5%对87.6%(HR 3.72 [95%CI 1.93–7.15],P<.001)。
关键数值与推荐
- IG/TR阳性阈值定义为≥0.01%。
- 高危组定义:第2周期后IG/TR阳性且初诊WBC≥30×10⁹/L。
临床怎么用
- 异基因HSCT显著改善高危组DFS(HR 0.33 [95%CI 0.18–0.60],P<.001)。
- 标准风险组无论是否行异基因HSCT均结局良好。
- 作者认为本研究为利用MRD指导成人Ph+ ALL治疗策略提供了框架。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: BCR::ABL1 quantification is widely regarded as the standard for monitoring measurable residual disease (MRD) in Philadelphia chromosome-positive (Ph+) ALL. However, recent evidence of BCR::ABL1 multilineage involvement questions the significance of BCR::ABL1 MRD. We aimed to define the prognostic role of MRD as assessed by BCR::ABL1 or lymphoid-specific immunoglobulin/T-cell receptor (IG/TR) gene markers. PATIENTS AND METHODS: We conducted BCR::ABL1 and IG/TR quantification after each treatment cycle in 264 patients treated in the GRAAPH-2014 trial, which used four cycles of reduced-intensity chemotherapy with nilotinib, followed by hematopoietic stem-cell transplantation (HSCT). RESULTS: Comparing BCR::ABL1 and IG/TR MRD revealed residual BCR::ABL1-positive non-ALL cells in 98 (43%) of 228 patients, defining multilineage Ph+ ALL. Despite poorer BCR::ABL1 responses, patients with multilineage Ph+ ALL had similar disease-free survival (DFS; hazard ratio [HR], 0.83 [95% CI, 0.49 to 1.41]; P = .50). Although BCR::ABL1 response failed to predict outcomes, IG/TR positivity (≥0.01%) was strongly associated with lower DFS (after cycle 2, HR, 2.49 [95% CI, 1.40 to 4.40]; P = .002; after cycle 4, HR, 4.13 [95% CI, 1.82 to 9.38]; P = .001). In multivariable analysis, both IG/TR positivity after cycle 2 and initial WBC count ≥30 × 109/L predicted poorer DFS, enabling to define a high-risk group having a 4-year DFS of 56.5% compared with 87.6% (HR, 3.72 [95% CI, 1.93 to 7.15]; P < .001). Moreover, allogeneic HSCT significantly improved DFS in the high-risk group (HR, 0.33 [95% CI, 0.18 to 0.60]; P < .001), whereas the standard-risk group had favorable outcomes regardless of allogeneic HSCT. CONCLUSION: Our findings challenge the significance of BCR::ABL1 monitoring in adult Ph+ ALL and demonstrate the prognostic role of IG/TR MRD. This study provides a framework for using MRD to guide treatment strategies in adults with Ph+ ALL.
引用
- Kim R, Chalandon Y, Rousselot P, et al. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study. J Clin Oncol. 2024. PMID: 39028928. doi:10.1200/JCO.24.00108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。